This Article Full Text Full Text (PDF) Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a colleague Related articles in JOP Similar articles in this journal Alert me to new issues of the journal Download to citation manager Rights & Permissions Google Scholar Articles by Neubauer, M. Articles by Kolodziej, M. PubMed Articles by Neubauer, M. Articles by Kolodziej, M. Social Bookmarking                            What's this?

Commentary: Do Guidelines Influence Physician Practice Behavior? The Experience With Erythropoiesis-Stimulating Agents

Because this article has no abstract, we have provided an extract of the first 100 words of the full text.

Most oncologists have grown tired of the issue of erythropoiesis-stimulating agents (ESAs). The contentious debate over appropriate use of these agents in chemotherapy-induced anemia, the national coverage decision (NCD) of the Centers for Medicare and Medicaid Services, and finally the US Food and Drug Administration (FDA) label changes have led to dramatic changes in how these agents are used in clinical practice. This journey has not been a pleasant one. Was it necessary? Could adherence to evidence-based guidelines have provided the necessary discipline to ensure appropriate prescribing to optimize outcomes? In this issue of Journal of Oncology Practice, Naeim . . . [Click for More]

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

Related articles in JOP:

Patterns of Care in Community-Based Oncology Practices for Anemia Associated With Myelosuppressive Chemotherapy

Arash Naeim, Lyssa Friedman, Kimberly B. Whitlock, David J. Pasta, Eric P. Elkin, Deborah P. Lubeck, Hema N. Viswanathan, and John Glaspy
JOP 2009 5: 236-243. [Abstract] [Full Text]